BPLPHARMA1,560.00

Bharat Parenterals Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
View
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
Revenue from Operations212.0218.0
Other Income7.818.8
Total Income219.8236.8
Expenses
+ Cost of Materials Consumed132.7146.1
+ Purchases of Stock-in-Trade1.71.2
+ Changes in Inventories1.7-9.8
+ Employee Benefit Expense15.316.9
+ Finance Costs0.92.2
+ Depreciation & Amortisation6.75.8
+ Other Expenses32.542.2
Total Expenses191.4204.7
EBITDA28.121.4
EBIT21.515.5
Profit
Pretax Income28.432.2
+ Current Tax8.38.4
+ Deferred Tax-0.9-0.6
Tax Expense7.47.8
Net Income21.324.3
+ Other Comprehensive Income-0.20.0
Total Comprehensive Income21.124.4
Per Share
Basic EPS37.1142.14
Diluted EPS37.1142.14
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit75.980.5
Gross Margin %35.8236.93
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY23 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.